Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD)
Allergan Aesthetics (NYSE:ABBV) presented four e-posters at AAD on March 30, 2026, reporting Phase 3 and real-world aesthetics findings.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Allergan Aesthetics (NYSE:ABBV) presented four e-posters at AAD on March 30, 2026, reporting Phase 3 and real-world aesthetics findings.
Key TrenibotE results: investigational serotype E showed rapid onset (as early as 8 hours), shorter duration (2–3 weeks), consistent efficacy across three repeat open-label treatments, a consistent safety profile, and no neutralizing antibody development.
GLP-1 patient insights: 52% expressed facial concerns; 32% were new to practices; top barriers were cost (82%) and fear of unnatural results (58%).
Positive
- TrenibotE rapid onset with results as early as 8 hours
- No neutralizing antibody development observed over three treatments
- Consistent safety and efficacy across three sequential open-label treatments
- GLP-1 patient pool growth: 32% reported as new to practices
Negative
- Short duration of effect (2–3 weeks) may require frequent retreatment
- High reported cost barrier for GLP-1 patients (82%) could limit uptake
- Significant patient concern over unnatural results (58%) may reduce procedure conversion
Details
News Market Reaction – ABBV
On Mar 30, the day this news came out, ABBV closed 1.78% above the previous close.
Data tracked by StockTitan Argus for the Mar 30 session.
Key Figures
- Study duration
- 18 weeks
- Open-label Phase 3 TrenibotE glabellar lines study
- Repeat treatments
- Up to 3 treatments
- Sequential open-label TrenibotE glabellar line study
- Onset time
- 8 hours
- Earliest assessment time for TrenibotE effect
- Duration of effect
- 2–3 weeks
- TrenibotE treatment duration for glabellar lines
- Facial concern rate
- 52%
- GLP-1-treated patients expressing concern about facial appearance
- New patients to practice
- 32%
- GLP-1-treated patients reported as new to aesthetics practices
- Cost barrier
- 82%
- GLP-1 patients citing cost as barrier to aesthetic treatment
- Fear of unnatural results
- 58%
- GLP-1 patients citing fear of unnatural results as barrier
Historical Context
-
AMWC e-posters on TrenibotE and broader aesthetics portfolio differentiation.
-
JUVÉDERM campaign and consumer research on subtle, personalized HA outcomes.
-
Multi-year MLB partnership and charitable Striking Out Cancer initiative.
-
NImmune Biopharma mechanistic and translational LANCL2 data at IMMUNOLOGY2026.
-
Global survey and new AA Signature educational solutions for modern aesthetics.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
glabellar lines medical
glp-1 agonists medical
phase 3 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Poster presentation highlights investigational neurotoxin trenibotulinumtoxinE (TrenibotE), demonstrating rapid onset and a consistently favorable safety profile across studied patient populations
- Poster presentation explores mindset and characteristics of GLP-1 agonist-treated patients in aesthetic clinics
"At Allergan Aesthetics, we are dedicated to scientific research that reinforces customer and patient trust and confidence in our broad product portfolio," said John Maltman, Ph.D., vice president, global aesthetics medical affairs, Allergan Aesthetics. "Our data presented at AAD advance knowledge of our market-leading and emerging portfolio to deliver safe and effective treatments that address patients' aesthetic concerns."
Data from Safety and Efficacy of TrenibotulinumtoxinE Following Repeat Treatments for Glabellar Lines: Findings From an Open-Label Phase 3 Study report findings from an 18-week, open-label, Phase 3 study evaluating the safety and efficacy of repeat TrenibotE (up to 3 open-label treatments) for glabellar lines showed a consistent safety profile.
TrenibotE is an investigational first-in-class botulinum neurotoxin serotype E characterized by rapid results, as early as 8 hours after administration (earliest assessment time), and shorter duration of effect of 2-3 weeks. If approved, TrenibotE will be the first neurotoxin of its kind available to patients.
Key findings include:
- TrenibotE was well-tolerated over 3 sequential open-label treatments, showing a consistent safety profile, no new safety concerns, and no neutralizing antibody development
- TrenibotE rapidly reduced glabellar line severity, with consistent efficacy over 3 sequential open-label treatments based on investigator and participant assessments
Data in Population Trends in Facial Aesthetic Concerns Among Patients Receiving GLP-1 Agonists for Weight Loss was obtained from an electronic survey of health care professionals in
The population of GLP-1 patients seeking aesthetic treatment is growing rapidly across all aesthetic specialties, with an estimated
Key findings include:
- Aesthetics health care professionals reported
32% of GLP-1-treated patients are new to their practice - Top two barriers preventing these patients from receiving aesthetic treatments include cost (
82% ) and fear of unnatural results (58% ) - Patients receiving GLP-1 treatment were reported to be predominantly white (
64% ), female (70% ), and 30-49 years of age (56% )
A complete list of e-posters presented at AAD are below.
E-Poster Title | Authors |
Population Trends in Facial Aesthetic Concerns | Cheryl Burgess, Mona |
Efficacy and Tolerability of a Topical Cosmetic | Shannon Humphrey, Priscilla |
Safety and Efficacy of TrenibotulinumtoxinE Following | Joely Kaufman-Jannette, William |
Patient Reported Satisfaction and Improvement of | Sue Ellen Cox, Melanie Palm, |
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Adelle Infante adelle.infante@allergan.com | Investors: Liz Shea liz.shea@abbvie.com |
View original content:SOURCE AbbVie
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.